Q-omics provides the consensus-scored MTND3P17 profile across patient tissues and cancer cell-line models. MTND3P17 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTND3P17 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MTND3P17 RNA expression shows 6,151 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, BRCA, and TGCT as cancer lineages where MTND3P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND3P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND3P17 survival associations across molecular data types. MTND3P17 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND3P17 RNA expression–survival associations across cancer types. High MTND3P17 expression shows unfavorable associations in KICH, MESO, LIHC, CHOL, THCA and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MTND3P17 RNA expression.
This table summarizes MTND3P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTND3P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND3P17 shows lower tumor expression in BRCA and higher tumor expression in LUSC. The BRCA box plot shows higher MTND3P17 RNA expression in normal versus tumor tissue (log2 FC = −0.042, t-test p = .045).
This table shows molecular features associated with MTND3P17 in patient tissues and cancer cell lines. In patient samples, MTND3P17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
